We are live on ! Find out more
ACM

Athyrium Capital Management Portfolio holdings

AUM $8.69M
1-Year Est. Return 34.58%
This Fund
S&P 500
This Quarter Est. Return
-9.16%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$281M
AUM Growth
+$808K
Cap. Flow
-$70.8M
Cap. Flow %
-25.16%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$4.64M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 58.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$73.3M 26.04%
8,857,268
– –
BIOR
2
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$34.6M 12.31%
119,423
– –
CMAX
3
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$33.5M 11.92%
149,574
– –
RVLP
4
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$13.8M 4.9%
8,148,832
– –
PBYI icon
5
Puma Biotechnology
PBYI
$398M
$5.16M 1.83%
+1,792,114
New +$4.64M
SCTL
6
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$3.96M 1.41%
2,202,420
– –

Similar funds

BGC
Birch Grove Capital New York $9.51M AUM 0.22% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
JDR
Jay D. Rosenbaum $6.69M AUM 4.68% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
KIM
Kaizen Investment Management Singapore $6.23M AUM
RJTCONH
Raymond James Trust Company of New Hampshire Portsmouth, New Hampshire $12.1M AUM 28.84% 1-Year Est. Return
HSC
Harbor Spring Capital New York $12.3M AUM
HVM
Harvest Volatility Management Norwalk, Connecticut $4.39M AUM 13.08% 1-Year Est. Return

Athyrium Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Athyrium Capital Management held 10 positions worth $281M, up 0.29% from $280M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Athyrium Capital Management withdrew a net $70.8M in Q1 2022.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 73% a quarter earlier.

Against the trend, Athyrium Capital Management opened a new position in Puma Biotechnology worth $5.16M.

  • Athyrium Capital Management's largest Q1 2022 buy was Puma Biotechnology: 1,792,114 shares worth $5.16M.
  • Athyrium Capital Management's ten largest holdings make up 100% of its $281M portfolio in Q1 2022.
  • Athyrium Capital Management opened 1 new position and closed 0 in Q1 2022.
  • Athyrium Capital Management's portfolio value rose 0.29% quarter-over-quarter to $281M.

Based on Athyrium Capital Management's 13F filing for Q1 2022, filed 16 May 2022.